SAB3500461
Anti-TL1A antibody produced in rabbit
IgG fraction of antiserum, buffered aqueous solution
Synonym(s):
Anti-TL1A
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
biological source
rabbit
conjugate
unconjugated
antibody form
IgG fraction of antiserum
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
predicted mol wt 28 kDa
species reactivity
mouse, rat, human
technique(s)
indirect ELISA: suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... TNFSF15(9966)
General description
Tumor necrosis factor ligand superfamily member 15 (TNFSF15) or TNF-like ligand 1A (TL1A) is a 174 amino acid, type II transmembrane protein. The molecular mass of the protein is 13kDa and it belongs to the tumor necrosis factor (TNF) family. TNFSF15 has a carboxyl terminal which is present on the exterior of the cell surface, a transmembrane domain and a short cytoplasmic tail. The gene encoding it is located on human chromosome 9q32.
Immunogen
TL1A antibody was raised against a peptide corresponding to 14 amino acids near the N-terminus of human TL1A.
Biochem/physiol Actions
Tumor necrosis factor ligand superfamily member 15 (TNFSF15)/TNF-like ligand 1A (TL1A) functions as an angiogenesis inhibitor by inhibiting the endothelial cell proliferation. It may play a role in angiogenesis-based cancer therapy. TNFSF15 activates the transcription factor κ B (NF-κB). It induces the degradation of its inhibitor (IκBα) and also aids the nuclear translocation of the p65 subunit of NF-κ B. c-Jun N-terminal kinase activation is initiated by TNFSF15 and it also inhibits the growth of various human tumor cell lines. Single nucleotide polymorphisms in the gene encoding this protein are associated with surgical diverticulitis and susceptibility to ulcerative colitis and Crohn′s disease.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Linkage
The action of this antibody can be blocked using blocking peptide SBP3500461.
Physical form
Supplied in PBS with 0.02% sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
related product
Product No.
Description
Pricing
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
新产品
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo.
Zhai Y
Faseb Journal (1999)
The TNFSF15 gene single nucleotide polymorphism rs7848647 is associated with surgical diverticulitis.
Connelly TM
Annals of Surgery (2014)
Associations between TNFSF15 polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: A meta-analysis.
Zhang J
Autoimmunity (2014)
VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth.
Oncogene (1999)
Shunsuke Kumanishi et al.
International journal of oncology, 55(1), 167-178 (2019-06-11)
Vascular endothelial growth inhibitor (VEGI; also referred to as TNFSF15 or TL1A) is involved in the modulation of vascular homeostasis. VEGI is known to operate via two receptors: Death receptor‑3 (DR3) and decoy receptor‑3 (DcR3). DR3, which is thus far
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service